{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T07:18:48Z","timestamp":1771485528196,"version":"3.50.1"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007184","name":"Yale School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007184","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jaad.2025.09.049","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:20:44Z","timestamp":1758576044000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Regional and insurance-based differences in biologic initiation for psoriasis among Medicare and commercially insured individuals in the United States: A Merative Marketscan analysis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2669-770X","authenticated-orcid":false,"given":"Qiwei Wilton","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7709-0548","authenticated-orcid":false,"given":"Jeffrey M.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jaad.2025.09.049_bib1","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jaad.2024.07.1490","article-title":"Geographic trends in psoriasis injectable biologic prescriptions by dermatologists among medicare beneficiaries","volume":"91","author":"Sun","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.09.049_bib2","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.jaad.2019.10.014","article-title":"Where you live matters: regional differences in health care resource use for psoriasis in the United States","volume":"82","author":"Nguyen","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2025.09.049_bib3","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1080\/14712598.2022.2132143","article-title":"Anti-IL 23 biologics for the treatment of plaque psoriasis","volume":"22","author":"Vu","year":"2022","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.jaad.2025.09.049_bib4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1186\/1472-6963-14-469","article-title":"Factors affecting the uptake of new medicines: a systematic literature review","volume":"14","author":"Lubl\u00f3y","year":"2014","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"10.1016\/j.jaad.2025.09.049_bib5","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/jamadermatol.2025.0669","article-title":"Use and cost of first-line biologic medications to treat plaque psoriasis in the US","volume":"161","author":"Rome","year":"2025","journal-title":"JAMA Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225028671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225028671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:28:40Z","timestamp":1765960120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225028671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":5,"alternative-id":["S0190962225028671"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.09.049","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regional and insurance-based differences in biologic initiation for psoriasis among Medicare and commercially insured individuals in the United States: A Merative Marketscan analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.09.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}